RSBT-001
COPD, Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, and other pulmonary inflammatory diseases
Key Facts
About RS BioTherapeutics
RS BioTherapeutics is a private, pre-revenue biotech company pioneering a novel approach to treating pulmonary inflammatory diseases. Its core asset, RSBT-001, is a first-in-class therapeutic leveraging specific, immune-modulating cannabinoids to target inflammation in the lungs, with an initial focus on chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH). The company is in the preclinical stage, targeting an Investigational New Drug (IND) application filing in 2026, and is led by a team of industry veterans and supported by a therapeutic expert council. Its strategy aims to address a significant unmet need for non-steroidal anti-inflammatory treatments in large respiratory markets.
View full company profile